Commercial & Development Revenue was CG Oncology’s largest product and service line in fiscal 2025, bringing in $3.23M of $4.04M (80%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Commercial & Development Revenue | — | — | $3.23M |
| License & Collaboration Revenue | $204.00K | $1.14M | $806.00K |
| Total | $204.00K | $1.14M | $4.04M |
CG Oncology brought in $4.04M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. CG Oncology regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $1.14M. Commercial & Development Revenue was the largest at $3.23M (80.0%), ahead of License & Collaboration Revenue at $806.00K (20.0%).
CG Oncology began breaking out Commercial & Development Revenue in fiscal 2025, when it brought in $3.23M.
CG Oncology (CGON) reports its revenue by product and service. In fiscal 2025, Commercial & Development Revenue was its largest product and service line, bringing in $3.23M (80.0% of the total), followed by License & Collaboration Revenue at $806.00K (20.0%).
Commercial & Development Revenue was CG Oncology's largest product and service line in fiscal 2025, bringing in $3.23M, or 80.0% of the $4.04M total across its two product and service lines.
Every figure comes from CG Oncology's annual financial filings, as reported. Each line keeps the name CG Oncology gives it, and years follow its fiscal calendar.
CG Oncology's revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.